Search research articles
Contact Us
Filters
Showing results (881-890 of 1,012) with videos related to
Page
of 102
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2020
Standardization of <sup>18</sup>F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni, Cristina Nanni, Luca Dozza, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
British Journal of Haematology
|
December 23, 2024
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study
Federico Stella, Annalisa Chiappella, Martina Magni, et al.
Annals of Hematology
|
September 21, 2023
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
Gregorio Barilà, Francesca Maria Quaglia, Anna Furlan, et al.
Leukemia
|
June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
F Cavallo, S Bringhen, G Milone, et al.
Blood
|
September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Blood
|
September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen, Alessandra Larocca, Davide Rossi, et al.
BMC Cancer
|
November 25, 2020
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
Luca Castagna, Alessandro Busca, Stefania Bramanti, et al.
Eclinicalmedicine
|
July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Stefania Oliva, Elisa Genuardi, Laura Paris, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Page
of 102
Search research articles
Search
Showing results (881-890 of 1,012) with videos related to
Sort By:
Page
of 102
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 2020
Standardization of <sup>18</sup>F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni, Cristina Nanni, Luca Dozza, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Roberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
British Journal of Haematology
|
December 23, 2024
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study
Federico Stella, Annalisa Chiappella, Martina Magni, et al.
Annals of Hematology
|
September 21, 2023
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
Gregorio Barilà, Francesca Maria Quaglia, Anna Furlan, et al.
Leukemia
|
June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
F Cavallo, S Bringhen, G Milone, et al.
Blood
|
September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Blood
|
September 3, 2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen, Alessandra Larocca, Davide Rossi, et al.
BMC Cancer
|
November 25, 2020
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients
Luca Castagna, Alessandro Busca, Stefania Bramanti, et al.
Eclinicalmedicine
|
July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Stefania Oliva, Elisa Genuardi, Laura Paris, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Page
of 102